Efficacy of the Novel Diamidine Compound 2,5-Bis(4-Amidinophenyl)-Furan-Bis- O -Methlylamidoxime (Pafuramidine, DB289) against Trypanosoma brucei rhodesiense Infection in Vervet Monkeys after Oral Administration (cid:1)

Owing to the lack of oral drugs for human African trypanosomiasis, patients have to be hospitalized for 10 to 30 days to facilitate treatment with parenterally administered medicines. The efficacy of a novel orally administered prodrug, 2,5-bis(4-amidinophenyl)-furan-bis- O -methlylamidoxime (pafuramidine, DB289), was tested in the vervet monkey ( Chlorocebus [ Cercopithecus ] aethiops ) model of sleeping sickness. Five groups of three animals each were infected intravenously with 10 4 Trypanosoma brucei rhodesiense KETRI 2537 cells. On the seventh day postinfection (p.i.) in an early-stage infection, animals in groups 1, 2, and 3 were treated orally with pafuramidine at dose rates of 1, 3, or 10 mg/kg of body weight, respectively, for five consecutive days. The animals in groups 4 and 5 were treated with 10 mg/kg for 10 consecutive days starting on the 14th day p.i. (group 4) or on the 28th day p.i. (group 5), when these animals were in the late stage of the disease. In the groups treated in the early stage, 10 mg/kg of pafuramidine completely cured all three monkeys, whereas lower doses of 3 mg/kg and 1 mg/kg cured only one of three and zero of three monkeys, respectively. Treatment of late-stage infections resulted in cure rates of one of three (group 4) and zero of three (group 5) monkeys. These studies demonstrated that pafuramidine was orally active in monkeys with early-stage T. brucei rhodesiense infections at dose rates above 3 mg/kg for 5 days. It was also evident that the drug attained only minimal efficacy against late-stage infections, indicating the limited ability of the molecule to cross the blood-brain barrier. This study has shown that oral diamidines have potential for the treatment of early-stage sleeping sickness. (detection limit, 10 3 trypanosomes/ml of blood). Blood collected by inguinal venipuncture was used for parasitemia determinations using both the wet-film and HCT methods. For estimation of parasites in the CSF, some of the free-flowing CSF was collected into a capillary tube and immediately transferred into a hemocytometer chamber to count the number of trypanosomes and white cells. Negative CSF samples were then centrifuged and reexamined for trypanosomes. In cases where no parasites were detected in either blood or CSF by the above-described methods, Swiss white mice were used to test for the presence of trypanosomes (11). Samples of 0.2 ml of blood or CSF were inoculated intraperitoneally into two mice per sample.

[1]  R. Brun,et al.  Efficacy of the diamidine DB75 and its prodrug DB289, against murine models of human African trypanosomiasis. , 2008, Acta tropica.

[2]  J. Ndung'u,et al.  Haematology of experimental Trypanosoma brucei rhodesiense infection in vervet monkeys , 2008 .

[3]  D. Masiga,et al.  Trypanosoma brucei rhodesiense Transmitted by a Single Tsetse Fly Bite in Vervet Monkeys as a Model of Human African Trypanosomiasis , 2008, PLoS neglected tropical diseases.

[4]  Simon Croft,et al.  Kinetoplastids: related protozoan pathogens, different diseases. , 2008, The Journal of clinical investigation.

[5]  Lea Berrang Ford Civil conflict and sleeping sickness in Africa in general and Uganda in particular , 2007, Conflict and health.

[6]  Human African trypanosomiasis (sleeping sickness): epidemiological update. , 2006, Releve epidemiologique hebdomadaire.

[7]  C. R. Bagnell,et al.  Distribution and quantitation of the anti-trypanosomal diamidine 2,5-bis(4-amidinophenyl)furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue. , 2004, Acta tropica.

[8]  H. Schmidt The pathogenesis of trypanosomiasis of the CNS , 2004, Virchows Archiv A.

[9]  C. Burri,et al.  Treatment of late stage sleeping sickness caused by T.b. gambiense: a new approach to the use of an old drug. , 2002, Swiss medical weekly.

[10]  P. Chiodini,et al.  African Trypanosomiasis in Travelers Returning to the United Kingdom , 2002, Emerging infectious diseases.

[11]  M. Massari,et al.  African sleeping sickness in tourists returning from Tanzania: the first 2 Italian cases from a small outbreak among European travelers. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  C. Burri,et al.  The phenomenon of treatment failures in Human African Trypanosomiasis , 2001, Tropical medicine & international health : TM & IH.

[13]  J. Keiser,et al.  Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment , 2001, Tropical medicine & international health : TM & IH.

[14]  J. Maguire,et al.  African trypanosomiasis in two travelers from the United States. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  K. Taylor,et al.  Immune response of cattle infected with African trypanosomes. , 1999, Memorias do Instituto Oswaldo Cruz.

[16]  M. Barrett,et al.  Trypanosomiasis and leishmaniasis: between the idea and the reality of control. , 1999, Parasitology today.

[17]  R. Brun,et al.  Animal Models of CNS (second-stage) Sleeping Sickness , 1999 .

[18]  J. Kerrigan,et al.  Anti-Pneumocystis Activities of Aromatic Diamidoxime Prodrugs , 1998, Antimicrobial agents and chemotherapy.

[19]  W D Wilson,et al.  2,5-bis[4-(N-alkylamidino)phenyl]furans as anti-Pneumocystis carinii agents. , 1998, Journal of medicinal chemistry.

[20]  W. Wilson,et al.  Dicationic diarylfurans as anti-Pneumocystis carinii agents. , 1995, Journal of medicinal chemistry.

[21]  J. Ndung'u,et al.  Total Protein and White Cell Changes in the Cerebrospinal Fluid of Vervet Monkeys Infected with Trypanosoma rhodesiense and the Post-treatment Reaction , 1994 .

[22]  C. Burri,et al.  Pharmacokinetics of melarsoprol in uninfected vervet monkeys. , 1994, Acta tropica.

[23]  W. Wilson,et al.  Different binding mode in AT and GC sequences for unfused-aromatic dications. , 1994, Journal of biomolecular structure & dynamics.

[24]  D. Harron Clinical pharmacokinetics: Concepts and applications (2nd edn.) , 1989 .

[25]  P. Mcneil,et al.  Trypanosomiasis and encephalitis: possible aetiology and treatment. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[26]  H. Schmidt,et al.  Trypanosoma brucei rhodesiense infection in vervet monkeys. II. Provocation of the encephalitic late phase by treatment of infected monkeys. , 1982, Tropenmedizin und Parasitologie.

[27]  P. Tukei,et al.  Preclinical testing of potential trypanocidal drugs in primates. Preliminary investigation of an experimental diamidine in vervets. , 1980 .

[28]  Patrick T.K. Woo The haematocrit centrifuge technique for the diagnosis of African trypanosomiasis. , 1970, Acta tropica.